Indrayani Biotech Ltd
Incorporated in 1992, Indrayani Biotech
Ltd is in the business of Foods & Hospitality, Engineering and Healthcare[1]
- Market Cap ₹ 62.8 Cr.
- Current Price ₹ 8.04
- High / Low ₹ 16.5 / 6.10
- Stock P/E 30.8
- Book Value ₹ 16.0
- Dividend Yield 0.00 %
- ROCE 4.24 %
- ROE 2.97 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.48 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 32.9%
- Company has a low return on equity of 1.21% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.5.10 Cr.
- Company has high debtors of 155 days.
- Promoter holding has decreased over last 3 years: -11.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 39 | 58 | 50 | 21 | 61 | 163 | 165 | 130 | 138 | 146 | |
| Sales growth | +20,563% | +48% | -58% | +195% | +165% | +2% | -21% | +6% | +15% | ||
| 0 | 39 | 57 | 47 | 26 | 54 | 145 | 142 | 124 | 128 | 138 | |
| Operating Profit | -0 | 1 | 1 | 3 | -5 | 7 | 17 | 24 | 6 | 10 | 9 |
| OPM % | -105% | 1.9% | 0.9% | 6% | -24% | 11% | 11% | 14% | 4.9% | 7% | 6% |
| 0 | 0 | 0 | 0 | -4 | 0 | 4 | 1 | 3 | 5 | 5 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 2 | 6 | 10 | 12 | 10 | 9 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 3 | 4 | 5 |
| Profit before tax | -0 | 0 | 0 | 1 | -11 | 4 | 12 | 11 | -6 | 0 | 1 |
| Tax % | 0% | 150% | 300% | 0% | 0% | 0% | 3% | 5% | 6% | -620% | |
| -0 | -0 | -0 | 1 | -11 | 4 | 12 | 10 | -6 | 2 | 3 | |
| EPS in Rs | -0.14 | -0.17 | 2.25 | -3.28 | 1.30 | 2.56 | 1.40 | -1.34 | 0.47 | 0.41 | |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | -5% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | -38% |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -22% |
| 3 Years: | -49% |
| 1 Year: | -46% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 1% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 4 | 4 | 4 | 34 | 34 | 34 | 46 | 46 | 46 |
| Reserves | -6 | -0 | -0 | 27 | -15 | -10 | 12 | 22 | 27 | 27 |
| 0 | 0 | 0 | 14 | 16 | 19 | 79 | 113 | 137 | 128 | |
| 1 | 6 | 9 | 7 | 5 | 8 | 31 | 54 | 58 | 52 | |
| Total Liabilities | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 253 |
| 1 | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 58 | 60 | |
| CWIP | -0 | 0 | 0 | 14 | 14 | 13 | 14 | 20 | 26 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 4 | 7 | 21 | 11 | 22 | 85 | 151 | 184 | 166 | |
| Total Assets | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 253 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 6 | 0 | 4 | 16 | -30 | -7 | 32 | ||
| -3 | -0 | -4 | -1 | -1 | -47 | -16 | 25 | -13 | ||
| 2 | -1 | -1 | -0 | -3 | 33 | 44 | -18 | -15 | ||
| Net Cash Flow | 0 | 1 | 1 | -1 | 1 | 2 | -2 | -0 | 4 | |
| Free Cash Flow | -2 | 2 | 2 | -0 | 3 | -25 | -47 | -8 | 23 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 122% | 331% | 215% | -5% | 61% | 94% | -128% | -124% | 328% |
Ratios
Consolidated / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 26 | 26 | 52 | 84 | 84 | 67 | 87 | 165 | 155 |
| Inventory Days | 365 | 57 | 25 | 14 | 44 | 159 | 182 | 147 | ||
| Days Payable | 365 | 70 | 77 | 52 | 81 | 141 | 104 | 55 | ||
| Cash Conversion Cycle | 0 | 26 | 26 | 38 | 32 | 46 | 30 | 106 | 243 | 247 |
| Working Capital Days | -1,883 | -22 | -19 | 30 | -59 | -12 | 6 | 127 | 211 | 163 |
| ROCE % | 28% | 12% | -13% | 16% | 23% | 14% | 3% | 4% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees employees |
|
|||||||
| Number of Subsidiaries and Step-Down Subsidiaries entities |
||||||||
| Cities Served (A-Diet Express Hospitality) cities |
||||||||
| Farming Land (HSL Agri Solutions) acres |
||||||||
| Meals per Day Capacity (A-Diet Express) meals/day |
||||||||
| Boiler Manufacturing Capacity (Matrix Boilers) TPH |
||||||||
| Milk Procurement per Day (Dindigul Farm Product) liters/day |
||||||||
Extracted by Screener AI
Documents
Announcements
- Corporate Action-Outcome of Right issue
- Corporate Action-Outcome of Right issue
-
Board Meeting Intimation for Considering And Approving Draft Notice Of The 34Th Annual General Meeting.
- Board meeting on November 6, 2026 to consider the 34th AGM notice.
-
Appointment Of Secretarial Auditor Of The Company.
- Indrayani Biotech appointed new secretarial auditor and accepted CS/Compliance Officer resignation effective November 2, 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
- Indrayani Biotech appointed secretarial auditor and accepted Company Secretary’s resignation effective 2 November 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
-
Annual Report 2010
from bse
Business Overview:[1]
IBL has multiple business units managed
by an independent team of field experts.
It operates in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture and Infrastructure